摘要
本文利用小鼠、肾囊膜下移植法(SRCA)预测评价了金荞麦提取物金E和CD_1对12例肺癌组织块异种移植后治疗的敏感性,初步观察了两种提取物对荷瘤宿主的毒副作用。移植实验总可评价率为83.3％(10/12)。以移植前后癌组织体积改变OMU<-10为有效标准,金E和CD_1的有效比分别为4/10和2/10。肺鳞癌对金E治疗的敏感性高于其它组织类型的肺癌。两种提取物时宿主无明显毒副反应。利用SRCA法进行临床前期预测评价有苗头的抗癌剂尚属新的尝试。
Responsiveness of human lung cancer explants to extracts E and CD1 of Fagopyrum Cymosum (Trev)Meisn, a newly discovered antitumor agent of Chinese medicinal herb, was determined by subrenal capsule (SRC)assay. A total of 12 lung cancers were tested in which 60 xenografts were implanted. With a mean growth of>5 OMU (1 OMU=0.02mm) in the control animal an assay was considered evaluable.The trials provided an evaluable assay rate of 83.3%. Taking<-10 OMU of tumor xenograft size as standard of responsiveness extracts E and CD1 offered response rates of 40% and 20% respectively. Squamous cell carcinoma was more sensitive to E than other types of lung cancer. These findings were similar to the clinical effects of CD1 phase-I trials.SRC assay might be of value in predicting human tumor response to new antitumor drugs prior to clinical phase-I trials. The study also confirmed that extracts E and CD1. had no toxicity and side-effect to the mice.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1989年第5期309-312,共4页
Chinese Journal of Clinical Oncology
关键词
金荞麦
肺癌
Lung cancer
Chinese herb
Subrenal capsule assay
